Abstract
Introduction: Guideline recommendations are meant to help minimize morbidity and to improve the care of nonmuscle invasive bladder cancer (NMIBC) patients but studies have suggested an underuse of guideline-recommended care. The aim of this study was to evaluate the level of adherence of German and Austrian urologists to German guideline recommendations. Methods: A survey of 27 items evaluating diagnostic and therapeutic recommendations (15 cases of strong consensus and 6 cases of consensus) for NMIBC was administered among 14 urologic training courses. Survey construction and realization followed the checklist for reporting results of internet e-surveys and was approved by an internal review board. Results: Between January 2018 and June 2019, a total of 307 urologists responded to the questionnaire, with a mean response rate of 71%. The data showed a weak role of urine cytology (54%) for initial diagnostics although it is strongly recommended by the guideline. The most frequently used supporting diagnostic tool during transurethral resection of the bladder was hexaminolevulinate (95%). Contrary to the guideline recommendation, 38% of the participants performed a second resection in the case of pTa low-grade NMIBC. Correct monitoring of Bacille Calmette-Guérin (BCG) response with cystoscopy and cytology was performed by only 34% of the urologists. Conclusions: We found a discrepancy between certain guideline recommendations and daily routine practice concerning the use of urine cytology for initial diagnostics, instillation therapy with a low monitoring rate of BCG response, and follow-up care with unnecessary second resection after pTa low-grade NMIBC in particular. Our survey showed a moderate overall adherence rate of 73%. These results demonstrate the need for sharpening awareness of German guideline recommendations by promoting more intense education of urologists to optimize NMIBC care thus decreasing morbidity and mortality rates.
References
1.
Bray
F
, Ferlay
J
, Soerjomataram
I
, Siegel
RL
, Torre
LA
, Jemal
A
. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
. CA Cancer J Clin
. 2018
;68
(6
):394
–424
.2.
Sylvester
RJ
, van der Meijden
AP
, Oosterlinck
W
, Witjes
JA
, Bouffioux
C
, Denis
L
, . Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials
. Eur Urol
. 2006 Mar
;49
(3
):466
–7
; discussion 475–7. http://dx.doi.org/10.1016/j.eururo.2005.12.031.3.
van den Bosch
S
, Alfred Witjes
J
. Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review
. Eur Urol
. 2011 Sep
;60
(3
):493
–500
.4.
AWMF: Klassifikation S3 [Internet]. [cited 2021 Feb 2]. Available from: https://www.awmf.org/leitlinien/awmf-regelwerk/ll-entwicklung/awmf-regelwerk-01-planung-und-organisation/po-stufenklassifikation/klassifikation-s3.html.
5.
S3-Leitlinie Harnblasenkarzinom. 2020;400.
6.
Chamie
K
, Saigal
CS
, Lai
J
, Hanley
JM
, Setodji
CM
, Konety
BR
, . Compliance with guidelines for patients with bladder cancer: variation in the delivery of care
. Cancer
. 2011 Dec 1
;117
(23
):5392
–401
.7.
Chamie
K
, Saigal
CS
, Lai
J
, Hanley
JM
, Setodji
CM
, Konety
BR
, . Quality of care in patients with bladder cancer: a case report
. Cancer
. 2012 Mar 1
;118
(5
):1412
–21
.8.
Ehdaie
B
, Atoria
CL
, Lowrance
WT
, Herr
HW
, Bochner
BH
, Donat
SM
, . Adherence to surveillance guidelines after radical cystectomy: a population-based analysis
. Urol Oncol
. 2014 Aug
;32
(6
):779
–84
.9.
Eysenbach
G
. Improving the quality of Web surveys: the Checklist for Reporting Results of Internet E-Surveys (CHERRIES)
. J Med Internet Res
. 2004 Sep 29
;6
(3
):e34
.10.
Zeng
X
, Zhang
Y
, Kwong
JS
, Zhang
C
, Li
S
, Sun
F
, . The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review
. J Evid Based Med
. 2015 Feb
;8
(1
):2
–10
.11.
Schroeck
FR
, Lynch
KE
, Li
Z
, MacKenzie
TA
, Han
DS
, Seigne
JD
, . The impact of frequent cystoscopy on surgical care and cancer outcomes among patients with low-risk, non-muscle-invasive bladder cancer
. Cancer
. 2019 Sep 15
;125
(18
):3147
–54
.12.
Witjes
JA
, Palou
J
, Soloway
M
, Lamm
D
, Kamat
AM
, Brausi
M
, . Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS)
. BJU Int
. 2013
;112
(6
):742
–50
.13.
Lebentrau
S
, Lebentrau
J
, May
M
, Wick
AK
, Mathew
M
, Schostak
M
. [Results of a Questionnaire-Based Study on guideline adherence regarding adjuvant treatment recommendations for patients with non-muscle-invasive bladder cancer: just a disturbing sidelight?]
. Aktuelle Urol
. 2016 Sep
;47
(5
):408
–13
.14.
Datovo
JCF
, Neto
WA
, Mendonça
GB
, Andrade
DL
, Reis
LO
. Prognostic impact of non-adherence to follow-up cystoscopy in non-muscle-invasive bladder cancer (NMIBC)
. World J Urol
. 2019 Oct
;37
(10
):2067
–71
.15.
Hendricksen
K
, Aziz
A
, Bes
P
, Chun
FK
, Dobruch
J
, Kluth
LA
, . Discrepancy between European Association of Urology Guidelines and daily practice in the management of non-muscle-invasive bladder cancer: results of a European survey
. Eur Urol Focus
. 2019 Jul
;5
(4
):681
–8
.16.
Comploj
E
, Trenti
E
, Palermo
S
, Pycha
A
, Mian
C
. Urinary cytology in bladder cancer: why is it still relevant
. Urologia
. 2015 Dec
;82
(4
):203
–5
.17.
Gallagher
KM
, Gray
K
, Anderson
CH
, Lee
H
, Stewart
S
, Donat
R
, . “Real-life experience”: recurrence rate at 3 years with Hexvix® photodynamic diagnosis-assisted TURBT compared with good quality white light TURBT in new NMIBC-a prospective controlled study
. World J Urol
. 2017 Dec
;35
(12
):1871
–7
.18.
Soubra
A
, Risk
MC
. Diagnostics techniques in nonmuscle invasive bladder cancer
. Indian J Urol
. 2015 Dec
;31
(4
):283
–8
.19.
Chen
C
, Huang
H
, Zhao
Y
, Liu
H
, Luo
Y
, Sylvester
RJ
, . Diagnostic accuracy of photodynamic diagnosis with 5-aminolevulinic acid, hexaminolevulinate and narrow band imaging for non-muscle invasive bladder cancer
. J Cancer
. 2020
;11
(5
):1082
–93
.20.
Gakis
G
, Fahmy
O
. Systematic review and meta-analysis on the impact of hexaminolevulinate- versus white-light guided transurethral bladder tumor resection on progression in non-muscle invasive bladder cancer
. Bladder Cancer
. 2016 Jul 27
;2
(3
):293
–300
.21.
Kang
W
, Cui
Z
, Chen
Q
, Zhang
D
, Zhang
H
, Jin
X
. Narrow band imaging-assisted transurethral resection reduces the recurrence risk of non-muscle invasive bladder cancer: a systematic review and meta-analysis
. Oncotarget
. 2016 Nov 3
;8
(14
):23880
–90
.22.
Gontero
P
, Oderda
M
, Altieri
V
, Bartoletti
R
, Cai
T
, Colombo
R
, . Are referral centers for non-muscle-invasive bladder cancer compliant to EAU guidelines? a report from the Vesical Antiblastic Therapy Italian Study
. Urol Int
. 2011
;86
(1
):19
–24
.23.
Sylvester
RJ
, Brausi
MA
, Kirkels
WJ
, Hoeltl
W
, Calais Da Silva
F
, Powell
PH
, . Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder
. Eur Urol
. 2010 May
;57
(5
):766
–73
.24.
Hinotsu
S
, Akaza
H
, Naito
S
, Ozono
S
, Sumiyoshi
Y
, Noguchi
S
, . Maintenance therapy with bacillus Calmette-Guérin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer
. BJU Int
. 2011 Jul
;108
(2
):187
–95
.25.
Struck
JP
, Kramer
MW
, Katzendorn
O
, Hupe
MC
, Ozimek
T
, Hennig
MJP
, . Bicentric retrospective analysis of en bloc resection and muscularis mucosae detection rate in non-muscle invasive bladder tumors: a real-world scenario
. Adv Ther
. 2021 Jan
;38
(1
):258
–67
.26.
Masood
S
, Sriprasad
S
, Palmer
JH
, Mufti
GR
. T1G3 bladder cancer: indications for early cystectomy
. Int Urol Nephrol
. 2004
;36
(1
):41
–4
.27.
De Berardinis
E
, Busetto
GM
, Antonini
G
, Giovannone
R
, Gentile
V
. T1G3 high-risk NMIBC (non-muscle invasive bladder cancer): conservative treatment versus immediate cystectomy
. Int Urol Nephrol
. 2011 Dec
;43
(4
):1047
–57
.28.
Zhang
L
, Wu
B
, Zha
Z
, Zhao
H
, Yuan
J
, Jiang
Y
. Concomitant carcinoma in situ may not be a prognostic factor for patients with bladder cancer following radical cystectomy: a PRISMA-compliant systematic review and meta-analysis
. World J Urol
. 2020 Jan
;38
(1
):129
–42
.© 2021 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2021
You do not currently have access to this content.
